The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

• Status: Not yet recruiting
• Trial end date: 2028-12-31
• Target enrollment: 0
• Participant gender: All

Summary

CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD).

CAPTIVATE aims to find the best treatment, or combination of treatments, that slow the progression of CKD so that fewer people develop kidney failure.

CAPTIVATE provides a research platform that allows many treatment-related questions to be answered within a common trial set-up.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The George Institute
• Treatments: Endothelin Receptor Antagonists

Criteria

Inclusion Criteria:

1. Age ≥ 18 years

2. Known chronic kidney disease from any cause (eGFR ≥25 mL/min/1.73m2)

3. Currently receiving standard of care treatment according to treating physician

4. Eligible for randomisation in at least one recruiting domain-specific appendix

5. Participant and treating physician are willing and able to perform trial procedures

Exclusion Criteria:

1. Planned to commence kidney replacement therapy or kidney transplant surgery in next 6 months

2. Life expectancy less than 6 months